OTC Allergy Switch Approved For Bayer In US
Azelastine 0.15% Nasal Antihistamine Branded Astepro Allergy Is First-In-Class Switch
CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.
You may also be interested in...
Bayer Blames Macroeconomic Pressures For Lower Volumes In Q1
Inflationary pressures and supply constraints led to volume declines at Bayer Consumer Health in Q1. However, price rises offset these headwinds helping the business to post a 4% rise in sales.
Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda
Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.
Astepro Launch And Strong Cold Season Boost Bayer In Q3
The US OTC launch of reclassified nasal spray Astepro Allergy, in combination with “continuously elevated cold incidence rates,” helped to drive up Bayer's Consumer Health sales at a double-digit rate in Q3.